Interoffice Communication

MILES Berkeley, CA

Date May 8, 1987

CONFIDENTIAL

Subject Call from Dale Lawrence, M.D., CDC - 5/07/87

From C. Moore

To Call File

cc: L. Ambrus, P. Brown, J. D'Arco - WH, [redacted] - WH, E. Greene, W. Johnson, M. Mozen, E. Potere, V. Shalson, K. Simon, M. Sternberg

Dr. Lawrence phoned me to discuss his worldwide activity regarding monitoring seroconversion of haemophiliacs receiving heated, non-heated, screened and non-screened AHF products. He had heard from a physician in the United Kingdom that a possible seroconversion associated with our product had occurred in Italy and he wanted to check out the story. I discussed the Italian situation as we know it and stressed that there was nothing concrete linking our product to the seroconversion. After discussing the cases with him, (he was already aware of most of the details) he agreed that seroconversions could not be linked to our product and was of no concern for the CDC. He did indicate the one case the FDA and CDC continue to be concerned about is the case in Southern California with the inhibitor patient who received a million units of AHF. The AHF was screened and heated, (non Cutter source) and to date the AHF remains the assignable cause for the seroconversion.

RECEIVED
MAY 21 1987
PETE DeHART

CM/nal